Therapy involves patients living with relapsed or refractory multiple myeloma
Takeda has announced that the National Institute for Health and Care Excellence (NICE) has recommended Ninlaro with lenalidomide and dexamethasone.
The treatment – also known as ixazomib – as an option for treating relapsed or refractory multiple myeloma (RRMM) among adult patients who have received two or three lines of therapy…
